NeuroScientific Biopharmaceuticals Ltd. announced the appointment of Dougal Thring as Chief Operating Officer and Simon Scott as Director of Clinical Development, adding significant depth to its clinical leadership team prior to commencing first-in-human clinical studies for lead drug candidate EmtinBTM. Dougal was previously appointed as Vice President of Clinical Development at NeuroScientific in March 2021 and will move into the new position of Chief Operating Officer, working closely with the Executive Management team in overseeing all aspects of nonclinical and clinical research and development activities. Simon brings more than 15 years' of clinical research experience with a focus in the past 12 years in early phase clinical research, from clinic based roles at Hammersmith Medicines Research in London to senior management roles with Linear Clinical Research in Perth.

Most recently, Simon has held positions including Project Operations Manager, overseeing clinical operations, and Head of Business Development, overseeing front end services at Linear, including BD, start-up and recruitment teams, and thus involved in feasibility, scheduling, provision of protocol and wider document advice for all early phase projects through the company.